Table 4.

Patient demographics and disease characteristics, by IPAA surgical approach, among survey responders.

	Two-Stage IPAA (n=81)	Three-Stage IPAA (n=32)	P-value
Patient Demographics
Age (years), mean (SEM)	37.3 (1.4)	37.6 (2.6)	0.92
Female sex, N (%)	30 (37.5%)	17 (53.1%)	0.14
Race			0.44
White, N (%)	55 (90.2%)	17 (81.0%)
Hispanic, N (%)	3 (4.9%)	2 (9.5%)
Other, N (%)	3 (4.9%)	2 (9.5%)
Body mass index (kg/m2), mean (SEM)	25.6 (0.6)	24.7 (1.2)	0.44
Current smoker, N (%)	3 (3.8%)	1 (3.2%)	1.00
Age-adjusted CCI ≥1, N (%)	25 (31.7%)	9 (28.1%)	0.82
ASA ≥3, N (%)	11 (14.1%)	4 (13.3%)	1.00
History of prior abdominal surgery, N (%)	20 (25.6%)	6 (19.4%)	0.62
High-volume IBD surgeon, N (%)	74 (92.5%)	30 (93.8%)	1.00
Disease and Operative Characteristics
Steroid use at first operation, N (%)	56 (70.0%)	26 (83.9%)	0.16
Anti-TNF agent use at first operation, N (%)	26 (32.5%)	10 (32.3%)	1.00
Other immunomodulator use at first operation, N (%)	34 (42.5%)	6 (19.4%)	0.03
Indication for surgery			<0.001
Failure of medical management, N (%)	80 (98.8%)	22 (68.8%)
Perforation, N (%)	0 (0.0%)	5 (15.6%)
Toxic colitis, N (%)	0 (0.0%)	5 (15.6%)
Stricture, N (%)	1 (1.2%)	0 (0.0%)
Urgent procedure, N (%)	21 (26.3%)	24 (75.0%)	<0.001
Laparoscopic procedure, N (%)	22 (27.5%)	9 (28.1%)	1.00
Severe disease in specimen, N (%)	67 (83.8%)	27 (84.4%)	1.00
Severe disease at anastomosis, N (%)	42 (56.0%)	13 (43.3%)	0.28
Any disease at anastomosis, N (%)	71 (93.4%)	27 (90.0%)	0.69

IPAA: ileal pouch-anal anastomosis; SEM: standard error of the mean; CCI: Charlson-Comorbidity Index; ASA: American Society of Anesthesiologists; IBD: inflammatory bowel disease; TNF: tumor necrosis factor